Our K-M survival analysis also showed that ETV6/RUNX1-positive children receiving the SCCLG-ALL-2016 protocol had a 5-year estimate EFS and OS of 96.64 ± 2.2% and 97.48 ± 1.99%, respectively, significantly higher than those of GD-ALL-2008 protocol positive case at 88.97 ± 4.62% and 91.82 ± 4.07%, indicating that the SCCLG-ALL-2016 protocol is more suitable for ETV6/RUNX1-positive children and significantly improves the prognosis. The gene discussed is RUNX1; the disease is acute lymphoblastic leukemia.